Associate Professor, Medicine, University of Colorado School of Medicine
Oncology
Dr. Stephen Leong, MD
|
|
Give Review
Stephen Leong practices Oncology. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Stephen Leong is a published MD as well. He has 25 publications published. The latest was: Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary c... Stephen Leong accepts all Medicare patients.
Publications
- Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and Biliary c...
- Esophageal and esophagogastric junction Cancers, version 1.2015.
- Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer.
- A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid Tumors.
- Phase 1 study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid Malignancies.
- From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development.
- Overcoming IGF1R/IR Resistance Through Inhibition of MEK Signaling in Colorectal Cancer Models.
- MetaAnalysis of Survival, Complications, and Imaging Response following Chemotherapy-based Transarterial Therapy in Patients with Unresectable Intrahepatic Cholangioca...
- A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid Tumors.
- Patient-derived tumour xenografts as models for oncology drug development.
- An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid Tumors with adequate and moderately impaired hepatic function.
- Promising targets and drugs in development for colorectal Cancer.
- A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced Cancer.
- Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal Cancer.
- The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against ...
- Development of an integrated genomic classifier for a novel agent in colorectal Cancer: approach to individualized therapy in early development.
- Novel agents in the treatment of metastatic colorectal Cancer.
- A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid Tumors.
- Endoscopic-assisted closure of persistent gastrocutaneous fistula with a porcine fistula plug: report of a new technique.
- Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth fact...
- Results of a phase I trial of 12 patients with locally advanced Pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of ...
- Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid Malignancies: results of a phase I and phar...
- Phase I pharmacokinetic and pharmacodynamic study of the oral, Small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients w...
- A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid Tumors.
Schools
Royal College Of Surgeons In Ireland
Beaumont Hospital Dublin Ireland
Albert Einstein Healthcare Network Program
University Of Colorado University Hospital Program
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Pathway X Bronze Direct CACA IN HIX
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Great West Healthcare-Cigna PPO
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- HealthSmart
- Humana
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Colorado -
Albert Einstein Healthcare Network -
Royal College of Surgeons Ireland
Hospital
-
University of Colorado Hospital
Drug Facts
| NPI NUMBER | 1194862466 | |
| NPPES Provider LastName | LEONG | |
| NPPES Provider FirstName | STEPHEN | |
| NPPES Provider ZIPCode | 800452545 | |
| NPPES Provider State | CO | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 263.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 39.0 | |
| Percent Opioid Claims | 14.83 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1194862466 |
| Last Name Of The Provider | LEONG |
| First Name Of The Provider | STEPHEN |
| View All |
Similar Doctors
|
Dr. Thomas W. Flaig, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Christopher H. Lieu, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William E. Daniel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Catherine E. Klein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eun-Kyung Im, MD |
|
|
Dr. Karl D. Lewis, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Wells A. Messersmith, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|